Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers.

Molecular cancer therapeutics·2026
Same author

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Oncogene·2026
Same author

Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trial.

British journal of cancer·2026
Same author

Surufatinib plus toripalimab for patients with advanced solid tumors and disease progression after prior immunotherapy: an open-label multi-cohort phase 2 trial.

Cancer immunology, immunotherapy : CII·2026
Same author

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Nature medicine·2026

相关实验视频

Updated: Jan 16, 2026

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.4K

优化CAR T细胞治疗固体瘤:临床视角

Jiarui Li1, Chang Liu2, Panpan Zhang2

  • 1Beijing Key Laboratory of Cell and Gene Therapy for Solid Tumors, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing, China.

Nature reviews. Clinical oncology
|October 2, 2025
PubMed
概括

化学抗原受体 (CAR) T细胞疗法在固体瘤中显示出前景. 本综述详细介绍了改善CAR T细胞疗效和安全性的策略,并解决了临床应用的关键挑战.

更多相关视频

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

相关实验视频

Last Updated: Jan 16, 2026

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.4K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.0K
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

54.0K

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 细胞疗法细胞疗法

背景情况:

  • 化学抗原受体 (CAR) T细胞疗法已经改变了血液癌症治疗.
  • 对于其在固体瘤中的应用仍然存在重大挑战.

研究的目的:

  • 审查完善CAR T细胞治疗固体瘤的关键进展.
  • 为优化疗效和安全提供实用的临床见解.

主要方法:

  • 讨论针对疗效和毒性的抗原选择.
  • 对策略的审查,包括分泌,制造,淋巴缺血和输送方法.
  • 检查响应评估和毒性管理框架.

主要成果:

  • 优化抗原选择可以提高疗效,同时最大限度地减少瘤外毒性.
  • 早期干预和特定的输送方法可以改善T细胞的适应性和治疗度.
  • 重复输注和强有力的毒性管理对于长时间的效果和安全至关重要.

结论:

  • 对固体瘤来说,对CAR T细胞疗法的系统优化至关重要.
  • 解决抗原选择,输送和毒性管理方面的挑战将改善患者的治疗结果.
  • 本综述提供了一个全面的指南,用于在固体恶性瘤中推进CAR T细胞治疗.